Losartan Potassium Tablet, Film Coated
Product Images NDC 50090-4910

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-4910). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500904910)

Losartan Potassium 50 mg film coated tablets label from A-S Medication Solutions. The label includes the NDC 50090-4910-0, lot number, storage instructions to store at 68 to 77 degrees Fahrenheit and protect from light, and indicates a bottle count of 90 tablets. Manufacturer information for Hetera Labs Limited is also present.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over study months between Losartan Potassium and Atenolol. The graph shows a gradually increasing trend for both drugs, with Atenolol having a slightly higher percentage. The study indicates an adjusted risk reduction of 13% favoring Losartan Potassium, with a p-value of 0.021.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a study period of 66 months between two treatments: Atenolol and Losartan potassium. The graph shows a consistently higher percentage of stroke in the Atenolol group versus the Losartan potassium group, indicating an adjusted risk reduction of 25% with Losartan potassium.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot figure titled 'Primary Endpoint Events within Demographic Subgroups' comparing Losartan Potassium and Atenolol event rates across different demographic groups. It shows hazard ratios with 95% confidence intervals for primary composite events and stroke (fatal/non-fatal) with subgroup divisions by age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). Symbols indicate results favoring either Losartan Potassium or Atenolol.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with events over 48 months for Losartan Potassium versus placebo. The graph shows risk reduction and a p-value, illustrating the relative event rates between the Losartan Potassium and placebo groups over time.*

FDA Label Image

Losartanstructure (Losartanstructure)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.